Courtesy of Charleston Regional Business Journal
A biopharmaceutical company has opened a Goose Creek facility as part of its goal to establish 10 or more collection centers around the country by 2024, the company said in a news release..
New Jersey-based ADMA Biologics Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics.
Adam Grossman, president and CEO, said South Carolina and Gov. Henry McMaster expressed strong support for opening the new facility.
“The state’s impressive infrastructure and skilled workforce create a terrific foundation for ADMA to safely collect and process plasma, and we look forward to continuing to grow our operations in the state now and in the coming years,” he said in a statement.
McMaster was on hand April 23 for a ribbon cutting ceremony, which Grossman said helped create an even stronger beginning for the company.
Beneath the corporate umbrella, ADMA has seven plasma collection facilities at various stages of approval and development. The Lowcountry plasma center, located at 214 Saint James Ave., is the newest and is projected to need up to 50 health care workers at full capacity.
“Securing raw material plasma supply has never been more important than it is today, and we believe the series of recent acquisitions of plasma collection facilities validates this scarcity value,” Grossman said.
The Goose Creek center includes automated registration, high-tech collection equipment designed to shorten the donation process, free WiFi and individual flat-screen TVs at each donor station and trained, certified staff.
The company is on track to achieve its 2024 goal and Grossman said the expansion will support ADMA’s goal of producing “quarter-over-quarter revenue growth throughout 2021 and beyond.” The Goose Creek operations also will help ADAM create a fully integrated and self-sufficient plasma supply chain, ensure continuity of product supply and generate asset value for shareholders, the company said.
ADMA plans to file an application for a biologics license and anticipates a standard 12-month BLA review period by the Food and Drug Administration.
Until then, ADMA is allowed to collect plasma donations on site. Following the FDA’s approval, the company can then use the collections for further use in the manufacturing of life-saving therapies.